BridgeBio Pharma Flags April Tafamidis IP Trial, Celebrates Three Phase 3 Wins
CEO highlighted three Phase 3 readouts in ADH1, LGMD2I and achondroplasia that met or beat expectations and flagged a tafamidis IP trial scheduled for late April as the primary overhang. He also reported Atrubie’s quarterly prescription growth, expansion into heart failure practices and a 0.41 hazard ratio in variant patients.
1. Tafamidis Intellectual Property Trial
The intellectual property trial for tafamidis is set to begin in late April, focusing on Form I patent infringement and validity. BridgeBio anticipates Pfizer’s arguments to be strong and notes that a U.S. ruling will be final without appeal, with a highly probable outcome of exclusivity through 2035.
2. Positive Phase 3 Clinical Readouts
BridgeBio achieved positive Phase 3 results in ADH1, LGMD2I and achondroplasia, each meeting or exceeding expectations. CEO highlighted these wins as evidence of the company’s underlying value despite recent share price pullbacks.
3. Atrubie Commercial Momentum
Atrubie’s launch performance has shown quarterly prescription growth, supported by expanded patient identification into high-volume heart failure practices. Clinical data show a 0.41 hazard ratio in variant patients and efficacy in both AFib and non-AFib contexts, which could simplify prescribing.